Martin T King1,2, Paul L Nguyen1,2, Ninjin Boldbaatar1, Clare M Tempany2,3, Robert A Cormack1,2, Clair J Beard1,2, Mark D Hurwitz4, W Warren Suh5,6, Anthony V D'Amico1,2, Peter F Orio1,2. 1. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts. 2. Harvard Medical School, Boston, Massachusetts. 3. Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts. 4. Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania. 5. Department of Radiation Oncology, Ridley-Tree Cancer Center, Santa Barbara, California. 6. Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California.
Abstract
BACKGROUND: Partial prostate treatment has emerged as a potential method for treating patients with favorable-risk prostate cancer while minimizing toxicity. The authors previously demonstrated poor rates of biochemical disease control for patients with National Comprehensive Cancer Network (NCCN) intermediate-risk disease using partial gland treatment with brachytherapy. The objective of the current study was to estimate the rates of distant metastasis and prostate cancer-specific mortality (PCSM) for this cohort. METHODS: Between 1997 and 2007, a total of 354 men with clinical T1c disease, a prostate-specific antigen (PSA) level < 15 ng/mL, and Gleason grade ≤3 + 4 prostate cancer underwent partial prostate treatment with brachytherapy to the peripheral zone under 0.5-Tesla magnetic resonance guidance. The cumulative incidences of metastasis and PCSM for the NCCN very low-risk, low-risk, and intermediate-risk groups were estimated. Fine and Gray competing risk regression was used to evaluate clinical factors associated with time to metastasis. RESULTS: A total of 22 patients developed metastases at a median of 11.0 years (interquartile range, 6.9-13.9 years). The 12-year metastasis rates for patients with very low-risk, low-risk, and intermediate-risk disease were 0.8% (95% confidence interval [95% CI], 0.1%-4.4%), 8.7% (95% CI, 3.4%-17.2%), and 15.7% (95% CI, 5.7%-30.2%), respectively, and the 12-year PCSM estimates were 1.6% (95% CI, 0.1%-7.6%), 1.4% (95% CI, 0.1%-6.8%), and 8.2% (95% CI, 1.9%-20.7%), respectively. On multivariate analysis, NCCN risk category (low risk: hazard ratio, 6.34 [95% CI, 1.18-34.06; P = .03] and intermediate risk: hazard ratio, 6.98 [95% CI, 1.23-39.73; P = .03]) was found to be significantly associated with the time to metastasis. CONCLUSIONS: Partial prostate treatment with brachytherapy may be associated with higher rates of distant metastasis and PCSM for patients with intermediate-risk disease after long-term follow-up. Treatment of less than the full gland may not be appropriate for this cohort.
BACKGROUND: Partial prostate treatment has emerged as a potential method for treating patients with favorable-risk prostate cancer while minimizing toxicity. The authors previously demonstrated poor rates of biochemical disease control for patients with National Comprehensive Cancer Network (NCCN) intermediate-risk disease using partial gland treatment with brachytherapy. The objective of the current study was to estimate the rates of distant metastasis and prostate cancer-specific mortality (PCSM) for this cohort. METHODS: Between 1997 and 2007, a total of 354 men with clinical T1c disease, a prostate-specific antigen (PSA) level < 15 ng/mL, and Gleason grade ≤3 + 4 prostate cancer underwent partial prostate treatment with brachytherapy to the peripheral zone under 0.5-Tesla magnetic resonance guidance. The cumulative incidences of metastasis and PCSM for the NCCN very low-risk, low-risk, and intermediate-risk groups were estimated. Fine and Gray competing risk regression was used to evaluate clinical factors associated with time to metastasis. RESULTS: A total of 22 patients developed metastases at a median of 11.0 years (interquartile range, 6.9-13.9 years). The 12-year metastasis rates for patients with very low-risk, low-risk, and intermediate-risk disease were 0.8% (95% confidence interval [95% CI], 0.1%-4.4%), 8.7% (95% CI, 3.4%-17.2%), and 15.7% (95% CI, 5.7%-30.2%), respectively, and the 12-year PCSM estimates were 1.6% (95% CI, 0.1%-7.6%), 1.4% (95% CI, 0.1%-6.8%), and 8.2% (95% CI, 1.9%-20.7%), respectively. On multivariate analysis, NCCN risk category (low risk: hazard ratio, 6.34 [95% CI, 1.18-34.06; P = .03] and intermediate risk: hazard ratio, 6.98 [95% CI, 1.23-39.73; P = .03]) was found to be significantly associated with the time to metastasis. CONCLUSIONS: Partial prostate treatment with brachytherapy may be associated with higher rates of distant metastasis and PCSM for patients with intermediate-risk disease after long-term follow-up. Treatment of less than the full gland may not be appropriate for this cohort.
Authors: Brian J Davis; Eric M Horwitz; W Robert Lee; Juanita M Crook; Richard G Stock; Gregory S Merrick; Wayne M Butler; Peter D Grimm; Nelson N Stone; Louis Potters; Anthony L Zietman; Michael J Zelefsky Journal: Brachytherapy Date: 2012 Jan-Feb Impact factor: 2.362
Authors: Andreas Blana; Stephen C W Brown; Christian Chaussy; Giario N Conti; James A Eastham; Roman Ganzer; Francois J Murat; Gilles Pasticier; Xavier Rebillard; John C Rewcastle; Cary N Robertson; Stefan Thuroff; John F Ward Journal: BJU Int Date: 2009-04-17 Impact factor: 5.588
Authors: John V Hegde; Robert V Mulkern; Lawrence P Panych; Fiona M Fennessy; Andriy Fedorov; Stephan E Maier; Clare M C Tempany Journal: J Magn Reson Imaging Date: 2013-05 Impact factor: 4.813
Authors: Michele Albert; Clare M Tempany; Delray Schultz; Ming-Hui Chen; Robert A Cormack; Sanjaya Kumar; Mark D Hurwitz; Clair Beard; Kemal Tuncali; Michael O'Leary; George P Topulos; Kristin Valentine; Lynn Lopes; Angela Kanan; Daniel Kacher; James Rosato; Hanne Kooy; Ferenc Jolesz; David L Carr-Locke; Jerome P Richie; Anthony V D'Amico Journal: Cancer Date: 2003-09-01 Impact factor: 6.860
Authors: Hikmat A Al-Ahmadie; Satish K Tickoo; Semra Olgac; Anuradha Gopalan; Peter T Scardino; Victor E Reuter; Samson W Fine Journal: Am J Surg Pathol Date: 2008-02 Impact factor: 6.394
Authors: Hashim U Ahmed; Richard G Hindley; Louise Dickinson; Alex Freeman; Alex P Kirkham; Mahua Sahu; Rebecca Scott; Clare Allen; Jan Van der Meulen; Mark Emberton Journal: Lancet Oncol Date: 2012-04-17 Impact factor: 41.316
Authors: Chana Weinstock; Daniel Suzman; Paul Kluetz; John Baxley; Charles Viviano; Amna Ibrahim; Jonathan Jarow; Raejshwari Sridhara; Ke Liu; Peter Carroll; Scott Eggener; Jim C Hu; Maha Hussain; Martin King; Eric Klein; Terry Kungel; Danil Makarov; Peter A Pinto; Brian Rini; Mack Roach; Howard Sandler; Peter N Schlegel; Daniel Song; Kirsten Goldberg; Richard Pazdur; Julia A Beaver Journal: J Urol Date: 2019-09-10 Impact factor: 7.450